当前位置: 首页 > 详情页

Clinical characteristics and prognosis of childhood rhabdomyosarcoma: a ten-year retrospective multicenter study

| 认领 | 导出 |

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Childrens Hosp, Beijing Key Lab Pediat Hematol Oncol,Natl Key Dis, Minist Educ,Hematol Oncol Ctr, Beijing 100045, Peoples R China; [2]Beijing Tong Ren Hosp, Dept Pediat, Beijing 100730, Peoples R China; [3]Peking Univ First Hosp, Beijing 100034, Peoples R China; [4]Beijing Shijitan Hosp, Beijing 100038, Peoples R China; [5]Wuhan Childrens Hosp, Wuhan 430000, Peoples R China; [6]Beijing Tong Ren Hosp, Beijing, Peoples R China; [7]Capital Med Univ, Beijing Childrens Hosp, Beijing, Peoples R China; [8]Shanghai Childrens Med Ctr, Shanghai, Peoples R China
出处:
ISSN:

关键词: Childhood RMS multicenter China

摘要:
Purpose: Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children. We have retrospectively explored the treatment results of childhood RMS and identified prognostic factors in multicenter in China, in order to lay the foundation for further multicenter study. Methods: This retrospective study was carried out analyzing the medical records of 161 patients with the pathological diagnosis of RMS from January, 2001 to February, 2014 at 5 large cancer centers in China. The data was reviewed clinico-epidemiological factors. Age, gender, histology type, primary site, tumor size, intergroup rhabdomyosarcoma study (IRS) group and results of treatments were evaluated. Patients were followed up to Dec 31, 2014. Results: The median age of our patients was 51 months. 10.5% of our patients were infants. The genitourinary system was the most common primary site of tumor (43.5%). The proportion of primary site of head and neck except parameningeal, at 28.2% (42 cases), while the proportion of parameningeal region was 4.6% (7 cases). The histological findings were as follows: 130 cases (80.7%) with embryonal, 19 cases (11.9%) with alveolar and 5 cases (3.1%) with botryoid type. According to the classification system of the IRS group, 1 case (0.6%) was group I, 54 cases (33.5%) were group II, 46 cases (28.6%) were group III and 60 cases (37.3 %) were group IV. 149 patients were treated and followed-up regularly, Patients in Beijing children's hospital (n=95) were enrolled in IRS-II/COG-D9803, D9802 protocols. while the other patients (n=54) started on treatment according to Chinese Anti-cancer Association protocol. There were median time of 51 months for following up, 60 occurred event. The ten-year event free survival rate was 53.4+/-5.1%, overall survival was 65.3+/-6.3%. The relations between outcome and age (0.046), primary site (0.022), pathologic subtype (0.013), tumor size (0.008) and IRS group (P=0.000) were associated significantly with event free survival. Among the variables, age (P=0.028) and IRS group (P=0.000) were associated significantly with overall survival. Multivariate analysis showed that overall survival for RMS was dependent on IRS group (P=0.026). Conclusions: The epidemiological characteristics of our patients are quite similarly to the worldwide data. Except for the higher prevalence of group IV in our patients and the higher percentage of patients with primary tumor site in the genitourinary system, this study showed that overall survival for RMS is depended on disease group.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2023]版:
JCR分区:
出版当年[2013]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Childrens Hosp, Beijing Key Lab Pediat Hematol Oncol,Natl Key Dis, Minist Educ,Hematol Oncol Ctr, Beijing 100045, Peoples R China;
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Childrens Hosp, Beijing Key Lab Pediat Hematol Oncol,Natl Key Dis, Minist Educ,Hematol Oncol Ctr, Beijing 100045, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院